

## Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

February 8, 2018

rivel - Ardelyx, Inc. (NASDAO: ARDX) today announced that Mike Reab, president and chief executive officer of Ardelyx, will participate in a freside chat at the Leerink Partners Global Healthcare Conference at 200 p.m. ET on Thursday, Feb. 15, 2018 in New York City.



To access the live webcast of Ardely's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at it andelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardelys, Inc.
Antely is toused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines. Andely is cardiorenal pipeline includes the Phase 3 development of tempanor for the treatment of hyperphosphatemia in people with end-stage renal diseases who are on dailysis and RDX013, a potassium secretagogue program for the presented resument of hyperphosphatemia in people with end-stage renal diseases who are on dailysis and RDX013, a potassium secretagogue program for the presented resument of hyperphosphatemia. In addition to its cardiorenal pipeline, Antely, has completed Phase 3 development of tempanor for the treatment of hyperphosphatemia in people with end-stage renal diseases who are on dailysis and RDX013, a potassium secretagogue program for the program for the treatment of hyperphosphatemia in people with end-stage renal diseases who are on dailysis and RDX013, a potassium secretagogue program for the present of tempanor for the treatment of hyperphosphatemia in people with end-stage renal diseases who are on dailysis and RDX013, a potassium secretagogue program for the present of tempanor for the treatment of hyperphosphatemia in people with end-stage renal diseases who are on dailysis and RDX013, a potassium secretagogue program for the present of tempanor for the treatment of hyperphosphatemia in people with end-stage renal diseases who are on dailysis and RDX013, a potassium secretagogue program for the peace of the peace

SOURCE Ardelyx

Monique Allaire, THRUST IR, 781-631-0759, monique @thrustir.com; Alicia Davis, THRUST IR, 910-620-3302, alicia @thrustir.com